New eye drops aim to tame pterygium redness
NCT ID NCT05794204
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested an eye drop called RMP-A03 in 77 healthy volunteers and people with pterygium, a fleshy growth on the eye. The goal was to see if it safely reduces redness and controls the condition. Participants received either a low dose, high dose, or placebo drops, and researchers measured changes in redness over 28 days.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- RMP-A03 eye drops
- What this could lead to
- If it works, this could lead to a non-surgical treatment to reduce redness and control pterygium growth.
- What could go wrong
- This is an early-phase trial with only 77 people, so results may not apply to everyone. The treatment may not work better than placebo, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
77 people
The number who actually took part.
- Started
-
Jun 2023
- Finished
-
Jan 2024
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Must be at least 18 years old * Diagnosis of pterygium with specified characteristics * BCVA of 20/200 or better * Willingness to attend all study visits and comply with the study procedures Exclusion Criteria: * Presence of ocular disease * Double pterygium * History of ocular surgery * Presence of ocular trauma * Use of any ocular medication * Use of contact lens * Allergy to any of the components of study drug * Cannot properly administer study drug * Clinically significant systemic disease that may place the subject at risk or confound study results * Participation in an investigational study within 30 days prior to screening * Female participants who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control (WOCBP).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pterygium are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Eye Research Foundation Inc
Newport Beach, California, 92663, United States
-
Global Research Management
Glendale, California, 91204, United States
-
Keystone Research
Austin, Texas, 78731, United States
-
Oceane7 Medical & Research Center Inc.
Miami, Florida, 33144, United States
-
Toyos Clinic
Nashville, Tennessee, 37215, United States
-
United Medical Research Institute
Inglewood, California, 90301, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Phone AI could spot eye disease in remote areas
- No-Stitch eye glue could spare patients pain and scarring
- Could donated tissue help heal stubborn wounds? new study investigates
- Eye gel may replace painful needle in pterygium surgery
- Eye surgery showdown: which technique best prevents pterygium return?
- Surgeons try apple vision pro during cataract operations